Paediatric drugs
Cure8 research brief
Why This Matters
Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.
Tracking paediatric trial activity helps families and clinicians know which drugs may become available sooner and where evidence gaps remain.
Who Should Pay Attention
Pediatric patients with IBD and their caregivers, pediatric gastroenterology clinicians, and researchers involved in paediatric IBD trials or drug development.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article is an abstract-summary review of clinical trial registries summarizing paediatric IBD interventional trials up to July 2, 2026.
It reports counts and categories of completed and active trials, highlights a mix of adult/pediatric recruitment in many completed studies, and lists biologic and small-molecule agents being assessed in paediatric populations.
The review is registry-based (ClinicalTrials.gov and ClinicalTrialsRegister.eu) and presents trial-level landscape data rather than trial results or new efficacy/safety findings. It notes delays in paediatric approvals relative to adults and suggests innovative trial designs and regulatory engagement to speed access.
This brief is grounded in the PubMed abstract provided and does not represent a full-text review beyond the supplied extract.
Keep In Mind
The source is an abstract-based review of trial registries (structured content depth: abstract). It summarizes trial counts and investigational agents but does not report clinical outcomes.
Paediatric trial recruitment often includes mixed adult/paediatric cohorts, which can delay pediatric-specific approvals; registry-derived data reflect planned and completed trials but not necessarily published results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPaediatric drugs
AuthorsDhruv Gupte, Nidhi Rashmikant Suthar, John K MacDonald +8 more
InstitutionDepartment of Paediatrics, McMaster University, Hamilton, ON, Canada.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 13, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declarations. Funding: None. Conflicts of Interest: DG: no conflicts to declare. NRS: no conflicts to declare. JKM: is a former employee of Alimentiv Inc. JL: is an employee of Alimentiv Inc. RJC: has received consulting fees from Alimentiv Inc. BGF: has received consulting fees from AbbVie, Abivax, Adiso, AgomAB Therapeutics, Akros, Alira Health, Ally Bridge Group, AnaptysBio, Apini Therapeutics, Argenx, Avoro Capital Advisors, Belmore Law, BioFactura, BioJamp, Biora Therapeutics, Blackbird Laboratories, Boehringer-Ingelheim, Boxer Capital, Celsius Therapeutics, Celgene/BMS, Celltrion, Clarivate, Connect BioPharma, Disc Medicine, Duality, EcoR1, Eli Lilly, Ensho Therapeutics, Evida, Enveda, Faes Farma, First Wave, Forbion, Galapagos, Galen Atlantica, Genentech/Roche, General Atlantic, Genesis Therapeutics, Gilead, Gossamer Pharma, GSK, Imhotex, ImmiDomics, Immunic Therapeutics, Intercept, Janssen, Japan Tobacco Inc., Klick Health, LifeMine Therapeutics, Mage Biologics, Merck, Mestag, Mirador Therapeutics, Mobius, Monte Rosa Tx, Morphic Therapeutics, Nexys Therapeutics, Nighthawk Therapeutics, Nimbus Therapeutics, Novartis, OncoC4, OrbiMed, Orphagen, Pendopharm, Pfizer, Protagonist, 32 Bio, REDX, Roche, Roivant/Televant, Sanofi, Sobi, Sorriso, Spyre Therapeutics, Surrozen Inc., Sun Pharma, Synedgen, Takeda, Teva, Triastek, Trex Bio, TR1X Inc. TVM Lifesciences, Ventyx Biosciences, Versant Ventures, Vida Ventures, and Zagbio; lecture fees from AbbVie, Takeda, Janssen, Pfizer, and Eli Lilly; payment for expert testimony from Belmore Law; participated in advisory boards for AbbVie, AnaptysBio, Boehringer-Ingelheim, Celgene/BMS Eli Lilly, Genentech/Roche, Janssen, Merck, MiroBio, Origo BioPharma, Pfizer, REDX Pharma, Sanofi, Takeda, Teva, Ecor1Capital, Morphic, and GSK; and has received stock or stock options from Connect BioPharma and EnGene. CC: no conflicts to declare. JH: has received speaker’s fees from AbbVie, Janssen, and Takeda; consulting fees from Alimentiv Inc. CM: has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Pendopharm, Pfizer, Prometheus Biosciences Inc., Roche, Sanofi, Takeda, Tillotts Pharma; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Organon, Pendopharm, Pfizer, Takeda; royalties from Springer Publishing; research support from Ferring, Pfizer. VJ: has received consulting/advisory board fees from AbbVie, Alimentiv, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, TopiVert, Ventyx, and Vividion; and speaker’s fees from AbbVie, Ferring, Bristol Myers Squibb, Galapagos, Janssen, Pfizer, Shire, Takeda, and Fresenius Kabi. EC: has received an educational grant and speaker fees from AbbVie, Pfizer, and consulting fees from AbbVie, Pfizer, Sanofi and Alimentiv Inc. Availability of Data and Materials: All relevant data are included within the article and its supplementary material. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Authors’ Contributions: Guarantors of the article: EC. Development of study concept and design: EC, RJC, VJ. Acquisition, analysis, and interpretation of the data: DG, NRS, CC, JKM, JL. Drafting of the manuscript: DG, NRS, CC, JKM, JL, EC. Critical revision of the manuscript for important intellectual content: EC, DG, NRS, JKM, JL, RJC, BGF, CC, JH, CM, VJ. All authors approved the final version of the manuscript. We respectfully acknowledge the contributions of Dr Brian Feagan, who passed away during the submission of this finalised manuscript. This manuscript, including related data, figures and tables has not been previously published and is not under consideration elsewhere.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Crohn's Disease Market Across The 7MM To Witness Upsurge In Growth From USD 9 Billion In 2023
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
Escalating Crohn’s Care: The Case for Dual Therapy
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.